ATE297751T1 - Kombinationstherapie mit keratinozyten- wachstumfaktor und ein epidermis-wachstumfaktor inhibitor - Google Patents

Kombinationstherapie mit keratinozyten- wachstumfaktor und ein epidermis-wachstumfaktor inhibitor

Info

Publication number
ATE297751T1
ATE297751T1 AT01916662T AT01916662T ATE297751T1 AT E297751 T1 ATE297751 T1 AT E297751T1 AT 01916662 T AT01916662 T AT 01916662T AT 01916662 T AT01916662 T AT 01916662T AT E297751 T1 ATE297751 T1 AT E297751T1
Authority
AT
Austria
Prior art keywords
growth factor
inhibitor
combination therapy
epidermis
keratinocyte
Prior art date
Application number
AT01916662T
Other languages
English (en)
Inventor
Penelope Elizabeth Miller
James Dale Moyer
Original Assignee
Pfizer Prod Inc
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22702391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE297751(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc, Osi Pharm Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE297751T1 publication Critical patent/ATE297751T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01916662T 2000-03-20 2001-03-15 Kombinationstherapie mit keratinozyten- wachstumfaktor und ein epidermis-wachstumfaktor inhibitor ATE297751T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19069700P 2000-03-20 2000-03-20
PCT/US2001/008207 WO2001070255A2 (en) 2000-03-20 2001-03-15 Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor

Publications (1)

Publication Number Publication Date
ATE297751T1 true ATE297751T1 (de) 2005-07-15

Family

ID=22702391

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01916662T ATE297751T1 (de) 2000-03-20 2001-03-15 Kombinationstherapie mit keratinozyten- wachstumfaktor und ein epidermis-wachstumfaktor inhibitor

Country Status (12)

Country Link
US (3) US20020061304A1 (de)
EP (1) EP1276496B1 (de)
JP (1) JP2003527437A (de)
AT (1) ATE297751T1 (de)
AU (1) AU2001243657A1 (de)
CA (1) CA2403721C (de)
DE (1) DE60111515T2 (de)
ES (1) ES2240430T3 (de)
MX (1) MXPA02009176A (de)
MY (1) MY124799A (de)
TW (1) TWI281402B (de)
WO (1) WO2001070255A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) * 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US20020077301A1 (en) * 2000-10-05 2002-06-20 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US7202066B2 (en) * 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
DK1871353T3 (da) * 2005-04-15 2011-04-04 Einstein Coll Med Vitamin k til forebyggelse eller behandling af hududslæt sekundært til anti-EGFR-terapi
US9428582B2 (en) * 2006-07-03 2016-08-30 Genmab A/S Method of treating rash in patients undergoing anti-EGFR therapy
DE102007026877A1 (de) * 2007-06-08 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Verwendung des Fibroblastenwachstumsfaktors 7 (Fgf7) und des Rezeptors Fgfr2b als Biomarker
US8815953B2 (en) * 2008-03-13 2014-08-26 Spectrum Pharmaceuticals, Inc. Formulations of vitamin K analogs for topical use
US20190086392A1 (en) 2016-03-21 2019-03-21 Inserm (Institut National De La Sante Et De La Recherch Medicale) Methods for diagnosis and treatment of solar lentigo
CA3085013A1 (en) 2017-12-13 2019-06-20 Onquality Pharmaceuticals China Ltd. A method for preventing or treating egfr-inhibition associated diseases
CN113975264A (zh) 2018-04-16 2022-01-28 上海岸阔医药科技有限公司 预防或治疗肿瘤疗法副作用的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN271295A0 (en) 1995-05-02 1995-05-25 Gropep Pty Ltd Method of treatment
HU220641B1 (hu) * 1993-03-26 2002-03-28 Amgen Inc. Keratinocita növekedési faktor alkalmazása
DK0815115T3 (da) * 1995-02-14 2003-09-15 Human Genome Sciences Inc Keratinocytvækstfaktor-2
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors

Also Published As

Publication number Publication date
AU2001243657A1 (en) 2001-10-03
EP1276496B1 (de) 2005-06-15
ES2240430T3 (es) 2005-10-16
DE60111515D1 (de) 2005-07-21
CA2403721A1 (en) 2001-09-27
EP1276496A2 (de) 2003-01-22
US20020061304A1 (en) 2002-05-23
JP2003527437A (ja) 2003-09-16
DE60111515T2 (de) 2006-05-11
MXPA02009176A (es) 2004-08-12
US7402557B2 (en) 2008-07-22
CA2403721C (en) 2009-06-09
TWI281402B (en) 2007-05-21
US20080206257A1 (en) 2008-08-28
US20040071697A1 (en) 2004-04-15
WO2001070255A3 (en) 2002-02-28
MY124799A (en) 2006-07-31
WO2001070255A2 (en) 2001-09-27

Similar Documents

Publication Publication Date Title
DE60111515D1 (de) Kombinationstherapie mit keratinozyten-wachstumfaktor und ein epidermis-wachstumfaktor inhibitor
BRPI0418745A (pt) anticorpo linhagem de células, composição farmacêutica, e, método de tratamento de cáncer em um paciente
EA200401355A1 (ru) Применение циклопамина при лечении псориаза и других кожных заболеваний
NO20022065L (no) Terapeutisk anvendelse
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
SG170730A1 (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
TW200612987A (en) Combination treatment for non-hematologic malignancies
TR200000576T1 (tr) Lipozomal kapsüllenmiş taksan uygulanması için bir yöntem
MX2010006519A (es) Metodo para tratar una fractura de hueso con anticuerpos anti-esclerostina.
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
HUP0202776A2 (hu) (+)-Tramadol, O-demetil-tramadol, (+)-O-demetil-tramadol, O-demetil-N-mono-demetil-tramadol, illetve (+)-O-demetil-N-mono-demetil-tramadol felhasználása vizeletinkontinencia kezelésére alkalmas gyógyszerkészítmény előállítására
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
DE60320398D1 (de) Methoden und medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebs
BR0313081A (pt) Combinação de um inibidor de aromatase com um bisfosfanato
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
DE69426530D1 (de) Pharmazeutische zusammensetzung zur förderung der gewebeheilung und -regenerierung und darreichungssatz
PT1251850E (pt) Utilizacao de uma preparacao de combinacao na terapia do cancro
PL367707A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
DE50109320D1 (de) Verwendung von 6-dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur therapie der harninkontinenz
ATE385798T1 (de) Pharmazeutische zubereitungen enthaltend azd 2171 und zd 6126 und verwendungen
DE50214008D1 (de) Arzneimittel zur behandlung von tumoren und deren metastasen unter verwendung eines bindemoleküls gegen das bone-sialoprotein
DE60309926D1 (de) Steroid-verbindungen mit anti-tumoraler wirkung
BRPI0409870A (pt) uso de irinotecano para tratamento de cáncer de mama resistente
PT1150981E (pt) Composto nucleosidico terapeutico
TW200500073A (en) Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties